Cebu Pacific Back To Full Year Profit After Pandemic Losses

Cebu Pacific soars to new heights with Php 90.6 billion in revenue for 2023, marking a 60% increase from the previous year!

FDA DG Assists Small Businesses With BBMSME Program, Joins First Lady in Tuguegarao

Food and Drug Administration Director General Dr. Samuel Zacate partners with Tuguegarao Mayor to empower local entrepreneurs through Bigyan-Halaga, Bangon Micro, Medium and Small Enterprises program.

Tala’s Iona Inigo-Mayo Shares Its Empowerment On The Organization And Its Customers

Gender-inclusive workplaces drive success! Tala empowers women, fostering leadership & financial independence, transforming lives and communities globally.

HONOR PH Introduces HONOR X7b, Another High-Quality Phone Without Breaking Your Wallet

HONOR Philippines locally debuts the durable, budget-friendly HONOR X7b, boasting impressive features like extended battery life and superb display.

Single-Shot Johnson & Johnson Vaccine Reveals 66% Efficacy Against Covid-19

0

Single-Shot Johnson & Johnson Vaccine Reveals 66% Efficacy Against Covid-19

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Medical Device Company, Johnson & Johnson has announced that the Janssen Covid-19 vaccine candidate was 66% effective overall in preventing moderate to severe Covid-19 cases, four weeks after the vaccination, a statement released on Friday, January 29.

Janssen Pharmaceutical Companies has developed a single-dose Covid-19 vaccine proven to be effective to nearly 44,000 participants who get their first shot, 468 of which are symptomatic. The clinical study of its efficacy was proven in the United States -72%, Latin America -66%, and less in South Africa-57% where the variant has taken root.

The company has stated that the new Janssen’s Covid-19 vaccine had an effectiveness of 85% against severe disease conducted across all the regions in the U.S, Latin America, and South Africa –resulted from 28 days after the inoculation.

The effectiveness of the vaccine has been seen to improve after 49 days –creating no severe cases in people who were vaccinated.

During the trial, those who were inoculated are completely covered against hospitalization and death. However, there was no patient recorded who have been hospitalized or died –28 days after the citizens receive the vaccine.

“These topline results with a single-shot COVID-19 vaccine candidate represent a promising moment,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson.

“A one-shot vaccine is considered by the World Health Organization to be the best option in pandemic settings, enhancing access, distribution and compliance,” Stoffels added.

If the Food and Drug Administration (FDA) approves, the Janssen Covid-19 vaccine will be distributed worldwide but with the following authorization. No final dates have been disclosed yet as to when it will finally be released in the market.

If authorized, Janssen’s single-shot vaccine can be stored for two years at -20°C (-4°F), at least three months of which can be at temperatures of 2-8°C (36°F–46°F). Unlike the two vaccines Pfizer and Moderna that require two-shot, the Janssen vaccine is given once. Also, Janssen can be stored in the same cold storage that it uses today, the company stated.

Further reports will follow as the company continues to participate in an ongoing clinical study.